Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile.
Melanoma Manag
; 7(2): MMT43, 2020 Jul 16.
Article
in En
| MEDLINE
| ID: mdl-32821375
ABSTRACT
BACKGROUND:
Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in node-positive melanoma patients but have limited power to determine if this benefit persists across various demographic factors. MATERIALS &METHODS:
We assessed the impact of demographic factors on the survival benefit of adjuvant immunotherapy in a database of 38,189 node-positive melanoma patients using the Kaplan-Meier method and Cox proportional hazards models.RESULTS:
All assessed demographic factors other than race significantly impacted survival of node-positive melanoma patients in univariate analysis. In multivariable analysis, only the age group interacted with immunotherapy.CONCLUSION:
Analysis of this large database of unselected node-positive melanoma patients demonstrated a positive survival benefit of immunotherapy across all demographic factors assessed and the impact was greater for patients 65 years of age and older.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Aspects:
Equity_inequality
Language:
En
Journal:
Melanoma Manag
Year:
2020
Document type:
Article
Affiliation country: